Related Experiment Videos
Adenosine triphosphate: a potential therapy for hypoxic pulmonary hypertension
C N Paidas1, D L Dudgeon, J A Haller
1Division of Pediatric Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Journal of Pediatric Surgery
|December 1, 1988
Summary
Low-dose infusion of adenosine triphosphate (ATP)-MgCl2 effectively reduced pulmonary hypertension caused by hypoxia in piglets. This treatment ameliorated vasoconstriction without significant systemic side effects.
Area of Science:
- Cardiovascular Physiology
- Pulmonary Hypertension Research
- Pharmacology
Background:
- Hypoxic pulmonary vasoconstriction (HPV) significantly elevates pulmonary artery pressure.
- Existing treatments for HPV may have systemic side effects.
Purpose of the Study:
- To investigate the efficacy of adenosine triphosphate (ATP)-MgCl2 infusion in ameliorating HPV.
- To assess the safety profile of ATP-MgCl2 in treating HPV.
Main Methods:
- Three-week-old piglets were subjected to hypoxia to induce pulmonary hypertension.
- Serial infusions of ATP-MgCl2 at varying doses were administered.
- Pulmonary and systemic arterial pressures, and cardiac output were monitored.
Main Results:
- Hypoxia significantly increased pulmonary artery pressure.
- ATP-MgCl2 infusions, particularly at low doses, significantly decreased mean pulmonary artery pressure (MPAP) by up to 30%.
- The reduction in MPAP was attributed to decreased pulmonary vascular resistance; systemic pressure was affected only at the highest dose.
Conclusions:
- Low-dose ATP-MgCl2 infusion effectively ameliorates HPV-induced vasoconstriction.
- The treatment demonstrates a favorable safety profile with minimal systemic side effects.
- ATP-MgCl2 shows promise as a therapeutic agent for hypoxic pulmonary hypertension.